- Home
- TPST
as 12-18-2024 1:43pm EST
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 27.2M | IPO Year: | N/A |
| Target Price: | $20.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $6.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tempest Therapeutics Inc. News
TPST Breaking Stock News: Dive into TPST Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The Wall Street Journal
13 days ago
A ‘Reverse Aging’ Guru’s Trail of Failed Businesses
Simply Wall St.
21 days ago
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock
GlobeNewswire
23 days ago
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
GlobeNewswire
2 months ago
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
GlobeNewswire
2 months ago
Tempest Extends Limited Duration Stockholder Rights Plan
Compare TPST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TPST Tempest Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.